MedTrace Logo

a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China

NCT05546125 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-04-18

No results posted yet for this study

Summary

This observational study will involve analysis of data collected by the National Rare Disease Registry or medical records .The study will describe outcomes only in PAH(Pulmonary arterial hypertension) patients treated with sildenafil; there will be no comparison with another treatment group.

Approximately 100 adults with PAH will be recruited in China hospitals This NIS(non-interventional study) data will be recorded by a physician in the medical records, during the patients' clinical visits, and in the electronic Case Report Forms (CRF).

Conditions

  • Pulmonary Arterial Hypertension (PAH)

Interventions

OTHER

as per Physician's prescription

Participants need to take the Revatio as per Physician's prescription

Sponsors & Collaborators

  • Pfizer Pharmaceuticals Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-23
Primary Completion
2023-02-27
Completion
2023-02-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05546125 on ClinicalTrials.gov